Moderna, Inc. reported unaudited product sales for 2024 ranging between $3.0 billion and $3.1 billion, with an ending cash balance of approximately $9.5 billion. The company also updated its expected revenue for 2025 to a range of $1.5 billion to $2.5 billion. In comparison, Moderna's annual revenues over recent years have shown significant fluctuations: $60 million in 2019, $803 million in 2020, $18.5 billion in 2021, $19.3 billion in 2022, and $6.8 billion in 2023. Meanwhile, Sarepta Therapeutics reported preliminary fourth-quarter and full-year 2024 net product revenue of $638.2 million, exceeding expectations of $585.1 million. The company reiterated its revenue guidance for 2025, projecting net product revenue between $2.9 billion and $3.1 billion. Additionally, Sarepta reported unaudited Elevidys sales of $384 million for the fourth quarter and $820 million for the full year, surpassing the consensus estimate of $329.1 million for the quarter.